AxoGen, Inc. provided revenue guidance for the year 2024. The company maintained its full year guidance with 2024 revenue in the range of $177 million to $181 million, which represents a growth rate of approximately 11% to 14%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.04 USD | +1.17% | +5.04% | -11.57% |
05-16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
05-02 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.57% | 261M | |
+12.15% | 228B | |
+14.90% | 196B | |
+18.22% | 141B | |
+29.15% | 110B | |
+0.53% | 65.88B | |
+16.92% | 54.3B | |
+6.33% | 52.39B | |
+10.93% | 45.22B | |
+5.87% | 37.12B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- Axogen, Inc. Provides Revenue Guidance for the Year 2024